Innate Pharma SA
PAR:IPH
Innate Pharma SA
PAR:IPH
Price:
1.194
EUR
8.15%
Market Closed
Market Cap:
€111.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Innate Pharma SA
PAR:IPH
|
FR |
Multiples-Based Value
The
Multiples-Based Value for
Innate Pharma SA (IPH)
under the Base Case is
0.848
EUR.
Compared with the current market price of 1.194 EUR, the stock appears
Overvalued by 29%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IPH
Multiples-Based Value
Base Case
0.848
EUR
Overvaluation 29%
Multiples Across Competitors
IPH Competitors Multiples
Innate Pharma SA Competitors
Innate Pharma SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Innate Pharma SA
PAR:IPH
|
110.1m EUR | 39.5 | -2.2 | -1.7 | -1.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.8B USD | 6.1 | 88.9 | 14.7 | 20.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.3B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.3B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.7B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41B EUR | 11.7 | 37.5 | 40.8 | 41.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD | 3 | 33.6 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
